German Vaccine Reforms Offer Multiple Tenders; Firms Want Purchase Guarantees
This article was originally published in The Pink Sheet Daily
Executive Summary
Government argues that shortages can be avoided by contracting with multiple manufacturers, but industry says changes do not go far enough, and is asking for sales assurances.
You may also be interested in...
Germany’s Vaccine Industry In Danger Of Disappearing, Says GSK
GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.
Novartis Flu Vaccine Problems Highlight Lack Of European Co-ordination
Quality issues that have seen two Novartis influenza vaccines suspended in a number of European countries have highlighted the shortfalls of a co-ordinated European approach to such problems.
AstraZeneca Blames Germany’s Tender System For Influenza Vaccine Shortages
AstraZeneca says that shortages of influenza vaccines in Germany are a direct result of the tendering process there, which has blocked the firm’s Fluenz nasal spray product from being prescribed in several federal states.